{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.4","upperLimit":"43.9","value":"32.5"}]}],"title":"MRD negative CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"15.6","value":"7.5"}]}],"title":"MRD positive CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"The MRD status by investigator refers to results of investigator assessment of bone marrow biopsy or bone marrow aspirate by immunohistochemistry and/or flow cytometry.\n\nThe CR with Positive or Negative MRD requires all of the following to be present:\n\n* No evidence of leukemic cells in the peripheral blood and/or by routine H/E staining of bone marrow. Minimal Residual Disease: CR with HCL evident in blood or marrow by flow cytometry.\n* Resolution of any hepatomegaly, splenomegaly, and abnormal (\\>= 2 cm minimum length) lymphadenopathy by CT or MRI. Although a normal spleen size is not defined, the maximum diameter of the spleen should be either \\< 17 cm or have decreased by \\>25% from its baseline.\n* Normal CBC as exhibited by: Neutrophils \\>= 1.5 x 10\\^9/L, Platelets \\>= 100 x 10\\^9/L, and hemoglobin \\>= 11.0 g/dL without transfusions or growth factors for at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"NUMBER","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, end of treatment, and at follow-up visits every 3 months for the next 24 months and every 6 months thereafter (Approximately 6 years)","title":"Percentage of Participants With MRD Positive or MRD Negative CR by Investigator's Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}